'Rasgap 317 326' presentation slideshows

RasGAP derived peptide for selective killing of cancer cells Description of the invention

Licensing Opportunity The University of Lausanne is proposing this technology for exclusive or non-exclusive license. Field : anti-cancer treatment. This new technology is designed to selectively target tumor cells and to increase efficacy of genotoxins . Development Phase

140 views • 6 slides